文献速递急性肾损伤血液净化与透析

肌酐-胱抑素C比值与接受强化治疗及连续性肾脏替代治疗患者的死亡率

Creatinine-Cystatin C Ratio and Mortality in Patients Receiving Intensive Care and Continuous Kidney Replacement Therapy: A Retrospective Cohort Study.
PubMed 文献 · Am J Kidney Dis · 2020-10-21

该回顾性队列研究纳入韩国某三级医疗中心1588例因急性肾损伤接受强化治疗和连续性肾脏替代治疗(CKRT)的患者,评估CKRT启动时基线血清肌酐-胱抑素C比值与90天死亡率的关系。结果发现,较高的肌酐-胱抑素C比值与较低的30天和90天死亡率显著相关,且经多变量调整后关联仍显著。

要点

  • CKRT启动时较高的肌酐-胱抑素C比值与更好的生存率独立相关。
  • 该比值或可作为AKI接受CKRT患者预后评估的辅助指标。
  • 研究为回顾性,AKI时肌酐和胱抑素C可能未达稳态,需谨慎解读。

核心结论

  • 在接受强化治疗和CKRT的AKI患者中,较高的血清肌酐-胱抑素C比值与更好的生存率相关。

研究设计与样本

  • 回顾性队列研究,纳入韩国某三级医疗中心1588例因AKI接受强化治疗和CKRT的患者。
  • 预测指标为CKRT启动时的基线血清肌酐-胱抑素C比值。
  • 主要结局为CKRT启动后90天死亡率(年龄和性别调整)。
  • 采用Cox比例风险模型评估比值与结局的关联。

主要发现

  • 患者平均年龄64.7±14.5岁,女性635例(40.0%)。
  • 肌酐-胱抑素C比值范围为0.08至10.48。
  • 较高肌酐-胱抑素C比值组的30天和90天死亡率显著较低。
  • 多变量Cox回归显示,随着比值四分位数升高,死亡风险 successively 降低。
  • 立方样条分析显示,比值越高,30天和90天死亡风险越低;调整混杂变量后关联仍显著。

临床怎么用

  • 对于接受CKRT的AKI患者,CKRT启动时的肌酐-胱抑素C比值可能有助于预后分层。
  • 该比值需结合临床情况解读,不能替代综合评估。

局限性

  • 回顾性分析。
  • AKI时血清肌酐和胱抑素C可能未处于稳态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Studies have suggested associations between lower ratios of serum creatinine to cystatin C with both lower muscle mass and adverse clinical outcomes in multiple disease conditions. Identifying risk factors for mortality among patients with acute kidney injury (AKI) undergoing continuous kidney replacement therapy (CKRT) may improve assessment of prognosis. We sought to evaluate the association of creatinine-cystatin C ratio with outcomes in patients with AKI undergoing CKRT. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: 1,588 patients treated with intensive care and CKRT for AKI at a tertiary Korean medical center. PREDICTOR: Baseline serum creatinine-cystatin C ratio at the time of CKRT initiation. OUTCOMES: Age- and sex-adjusted 90-day mortality after CKRT initiation. ANALYTICAL APPROACH: Cox proportional hazard models to estimate the association between creatinine-cystatin C ratio and outcome. RESULTS: Mean age was 64.7 ± 14.5 years and 635 patients (40.0%) were women. The range of creatinine-cystatin C ratios was 0.08 to 10.48. The 30- and 90-day mortality rates were significantly lower for the higher creatinine-cystatin C ratio groups. Multivariable Cox proportional hazards regression analyses revealed that mortality risk became successively lower across quartiles of greater creatinine-cystatin C ratio. When creatinine-cystatin C ratio was evaluated using cubic spline analyses, risks for both 30- and 90-day mortality were lower with higher creatinine-cystatin C ratios. These associations remained significant even after adjustment for confounding variables. LIMITATIONS: Retrospective analysis, serum creatinine and cystatin C may not be in steady state in the setting of AKI. CONCLUSIONS: Higher serum creatinine-cystatin C ratios were associated with better survival in patients receiving intensive care and CKRT.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Jung CY, Joo YS, Kim HW, et al. Creatinine-Cystatin C Ratio and Mortality in Patients Receiving Intensive Care and Continuous Kidney Replacement Therapy: A Retrospective Cohort Study. Am J Kidney Dis. 2020. PMID: 33098923. doi:10.1053/j.ajkd.2020.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。